Skip to: Content
Skip to: Site Navigation
Skip to: Search

December 3, 2008 2:55:50 AM CST



Congress to Probe 'Misleading' Drug Ads

Posted May 8, 08 3:10 AM CDT in Politics Science & Health Business 

(Newser) – A congressional panel will examine three ad campaigns as part of a move to tighten regulations on drug companies' direct-to-consumer marketing, the Wall Street Journal reports. The committee will focus on ads for cholesterol drugs Vytorin and Lipitor, and anemia drug Procrit, which has been promoted as an anti-fatigue drug despite FDA demands not to do so.

Pfizer officials will also be quizzed about ads in which the inventor of the artificial heart appears to be giving medical advice—despite never having practiced medicine. Spending on drug marketing has soared since rules were relaxed and companies have fought hard against efforts to tighten regulations.

Source Wall Street Journal

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon
House Oversight and Investigations subcommittee Chairman Rep. Bart Stupak, D-Mich., heads a subcommittee looking into drug advertising.   (AP Photo)
Lawmakers plan to scrutinize Schering-Plough's promotion of the cholesterol-lowering drug Vytorin .   (AP Photo)
Lawmakers plan to question Pfizer officials about potentially misleading ad campaigns for its drugs.   (AP Photo/Mark Lennihan, file)
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Threads (
1
 of 2)



Loading...

Premium Articles from HighBeam

Find more articles like this

Today's Most Popular

Loading...

Other Business Stories


What is Newser?

2008 Codie Finalist

Face it: there's too much news. At Newser a team of editors and writers culls the most important stories from hundreds of U.S. and international sources and reduces them to a headline, picture, and two paragraphs. It's the Newser guarantee: we can take any report or column or video and pack what you need to know into 120 words or less. Newser's short-form aggregation, visual format, and unique information tools help you get more of the kind of news you want, in a quicker and more entertaining way. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »